Letafati A, Mozhgani S, Marjani A, Amiri A, Siami Z, Mohammaditabar M
Med Oncol. 2023; 40(11):317.
PMID: 37792095
DOI: 10.1007/s12032-023-02177-5.
Roumeliotou A, Pantazaka E, Xagara A, Dimitrakopoulos F, Koutras A, Christopoulou A
Cancers (Basel). 2023; 15(1).
PMID: 36612166
PMC: 9818148.
DOI: 10.3390/cancers15010171.
Pai S, Yadav V, Kuo K, Pikatan N, Lin C, Chien M
Int J Mol Sci. 2021; 22(21).
PMID: 34768921
PMC: 8584253.
DOI: 10.3390/ijms222111492.
Tang N, Hu B, Zhang Y, Chen Z, Yu R
J Int Med Res. 2021; 49(5):3000605211016562.
PMID: 34038205
PMC: 8161885.
DOI: 10.1177/03000605211016562.
Wang X, Shen X, Yan Y, Li H
Biosci Rep. 2021; 41(4).
PMID: 33739396
PMC: 8026821.
DOI: 10.1042/BSR20204402.
SPRY4-IT1 promotes survival of colorectal cancer cells through regulating PDK1-mediated glycolysis.
Liu S, Huang F, Ye Q, Li Y, Chen J, Huang H
Anim Cells Syst (Seoul). 2020; 24(4):220-227.
PMID: 33029299
PMC: 7473003.
DOI: 10.1080/19768354.2020.1784274.
CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis.
Kallergi G, Hoffmann O, Bittner A, Papadimitriou L, Katsarou S, Zacharopoulou N
Ther Adv Med Oncol. 2020; 12:1758835919895754.
PMID: 32426042
PMC: 7222234.
DOI: 10.1177/1758835919895754.
Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its clinicopathological significance.
Sun Z, Xu L
Oncol Lett. 2019; 18(3):2819-2824.
PMID: 31452760
PMC: 6676455.
DOI: 10.3892/ol.2019.10639.
The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization.
Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A
Breast Cancer Res. 2019; 21(1):86.
PMID: 31370904
PMC: 6676640.
DOI: 10.1186/s13058-019-1166-4.
Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
Wu C, Wang X, Chok S, Man K, Tsang S, Chan A
Theranostics. 2018; 8(14):3737-3750.
PMID: 30083256
PMC: 6071527.
DOI: 10.7150/thno.25487.
Identification of Epithelial-Mesenchymal Transition-related Target Genes Induced by the Mutation of Smad3 Linker Phosphorylation.
Park S, Yang K, Park Y, Hong E, Hong C, Park J
J Cancer Prev. 2018; 23(1):1-9.
PMID: 29629343
PMC: 5886489.
DOI: 10.15430/JCP.2018.23.1.1.
Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks.
Xu S, Zhan M, Wang J
Cell Death Discov. 2017; 3:17069.
PMID: 29188076
PMC: 5702855.
DOI: 10.1038/cddiscovery.2017.69.
Targeting PDK1 for Chemosensitization of Cancer Cells.
Emmanouilidi A, Falasca M
Cancers (Basel). 2017; 9(10).
PMID: 29064423
PMC: 5664079.
DOI: 10.3390/cancers9100140.
Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.
Sharma A, Sharma K, Gupta A, Yadav A, Kumar A
World J Gastroenterol. 2017; 23(22):3978-3998.
PMID: 28652652
PMC: 5473118.
DOI: 10.3748/wjg.v23.i22.3978.
Long non-coding RNA UCA1 promotes gallbladder cancer progression by epigenetically repressing p21 and E-cadherin expression.
Cai Q, Jin L, Wang S, Zhou D, Wang J, Tang Z
Oncotarget. 2017; 8(29):47957-47968.
PMID: 28624787
PMC: 5564618.
DOI: 10.18632/oncotarget.18204.
CCR7 mediates human breast cancer cell invasion, migration by inducing epithelial-mesenchymal transition and suppressing apoptosis through AKT pathway.
Xu B, Zhou M, Qiu W, Ye J, Feng Q
Cancer Med. 2017; 6(5):1062-1071.
PMID: 28378417
PMC: 5430102.
DOI: 10.1002/cam4.1039.
Serine/Threonine Kinase 3-Phosphoinositide-Dependent Protein Kinase-1 (PDK1) as a Key Regulator of Cell Migration and Cancer Dissemination.
di Blasio L, Gagliardi P, Puliafito A, Primo L
Cancers (Basel). 2017; 9(3).
PMID: 28287465
PMC: 5366820.
DOI: 10.3390/cancers9030025.
Long non-coding RNA LINC00152 promotes gallbladder cancer metastasis and epithelial-mesenchymal transition by regulating HIF-1α via miR-138.
Cai Q, Wang Z, Wang S, Weng M, Zhou D, Li C
Open Biol. 2017; 7(1).
PMID: 28077595
PMC: 5303272.
DOI: 10.1098/rsob.160247.
Correlation of PDK1 expression with clinicopathologic features and prognosis of hepatocellular carcinoma.
Wang J, Liu F, Ao P, Li X, Zheng H, Wu D
Onco Targets Ther. 2016; 9:5597-602.
PMID: 27672330
PMC: 5024765.
DOI: 10.2147/OTT.S110646.
Short-form Ron is a novel determinant of ovarian cancer initiation and progression.
Moxley K, Wang L, Welm A, Bieniasz M
Genes Cancer. 2016; 7(5-6):169-81.
PMID: 27551332
PMC: 4979590.
DOI: 10.18632/genesandcancer.109.